[Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice].

Parkinson's disease cell differentiation cell replacement therapy embryonic stem cells induced pluripotent stem cells neuronal progenitors

Journal

Molekuliarnaia biologiia
ISSN: 0026-8984
Titre abrégé: Mol Biol (Mosk)
Pays: Russia (Federation)
ID NLM: 0105454

Informations de publication

Date de publication:
Historique:
received: 23 04 2020
accepted: 25 06 2020
entrez: 4 12 2020
pubmed: 5 12 2020
medline: 15 12 2020
Statut: ppublish

Résumé

Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.

Identifiants

pubmed: 33276357
doi: 10.31857/S0026898420060063
doi:

Types de publication

Journal Article Review

Langues

rus

Sous-ensembles de citation

IM

Pagination

939-954

Auteurs

N V Katolikova (NV)

Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, 199034 Russia.
Institute of Cytology, Russian Academy of Sciences, St. Petersburg, 194064 Russia.
nkatolikova@yandex.ru.

A B Malashicheva (AB)

Institute of Cytology, Russian Academy of Sciences, St. Petersburg, 194064 Russia.
Almazov National Medical Research Centre, Ministry of Health of Russian Federation, St. Petersburg, 197341 Russia.

R R Gainetdinov (RR)

Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, 199034 Russia.
Pirogov Clinic of High Medical Technologies, St. Petersburg State University, St. Petersburg, 199034 Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH